$0.5423
-0.0365-6.31%
Last update: Nov 10, 4:49 AM
The average analyst price target for Pasithea Therapeutics is $3, 417.2% above the current price. The one analyst covering it rates it Buy. The latest change came on Dec 8, 2025, when HC Wainwright & Co. initiated coverage of Pasithea Therapeutics with a Buy rating and a $3 price target.
Price Target Range — 2 Quarters
Analyst Consensus — 1 Analysts
Rating Trend — Last 9 Months
